Skip to Content
MHDO logo of information, insight, improvement
logo of Maine Quality Forum

Pricing Component Data - Rule Chapter 570

This data is covered under Rule Chapter 570 Uniform Reporting System for Prescription Drug Price Data Sets, which can be found on our Rules and Statutes page..

2026 Registration and Data Submission

Below are the important tasks and dates for the submission of 2026 Chapter 570 Prescription Drug Price Data.

Note: Please see the 3/25/2025 webinar deck and recording if you are not sure how to complete the necessary tasks.

Task Date
MHDO Prescription Drug Price Data Portal 2026 registration must be completed. 1/30/26
The MHDO produces and posts on its publicly accessible website a list of prescription drugs for which the manufacturer has met any
of the three criteria during the prior calendar year. 		1/30/26
The MHDO produces and posts on its publicly available website a list of drug product families for which it intends to request pricing component
data from manufacturers, wholesale drug distributors and pharmacy benefits managers. 		2/15/26
MHDO's data vendor, HSRI, notifies manufacturers, wholesale distributers and PBMs via email that prepopulated Pricing Component
Data templates, including specific NDCs for which reporting is required, are available for download from the MHDO Prescription Drug Price Data Portal. 		3/17/26
Completed Pricing Component Data templates are due. 5/16/26

Prior Years Webinar Decks and Recordings

January 2022 - Updates to MHDO Prescription Drug Price Data Portal

In January 2022, the MHDO released an update to the MHDO Prescription Drug Price Data Portal to include the revisions to 90-590 Chapter 570: Uniform Reporting System for Prescription Drug Price Data Sets.. A webinar was held 1/11/22 to discuss and respond to questions regarding Chapter 570 file format changes and other changes required in order to reconcile the rule with recent changes in Maine law.

Important Notes

  1. LD 686, An Act to Increase Prescription Drug Price Transparency passed in the last session as Public Law 2021, Chapter 305, and became effective October 18, 2021. Several provisions in Rule Chapter 570 were inconsistent with the new law. When this occurs, the statute overrides inconsistencies in the rule. The rule now includes three notes that address the inconsistencies in the new law and the earlier version of the proposed rule.
    1. As of reporting year 2022, the MHDO will be posting a list of these NDCs and the manufacturers will no longer have to make such notifications to the MHDO. PL 2021, c. 305, Sections 4 & 5 [Chapter 570 Section 2(B)(3), page 4]
    2. As of reporting year 2022, the MHDO will be posting a list of these NDCs and the manufacturers will no longer have to make such notifications to the MHDO. PL 2021, c. 305, Sections 4 & 5 [Chapter 570 Section 2(C)(1)(a), page 4]
    3. As of October 18, 2021, The MHDO may share information in the aggregate, even if it allows the identification of an individual drug, as long as it is not released in a manner that allows the determination of individual prescription drug pricing contract terms covering a manufacturer, wholesale drug distributor or pharmacy benefits manager. PL 2021, c. 305, Sections 7 & 9. (Chapter 570 Section (6)(B), page 11]
  2. Enforcement issue: The level of reporting for the Pharmacy Benefit Managers in Chapter 570 was agreed to in the HCIFS committee work session, but was inadvertently not included in the final version of the rule.
    Resolution: The Board of Directors of the MHDO hereby partially suspends enforcement of 90-590 CMR Chapter 570, Section 2(J)(3) so that the MHDO shall enforce collection of the pricing component data from Pharmacy Benefits Mangers only for the data relevant to Maine, rather than the United States, including for each NDC the Pricing Units Administered, the Total Pharmacy Reimbursement, the Total Payment Received, the Total Rebate Receivable, the Total Rebate Payable Amount and any additional information, if applicable.